Tempus AI Inc. (TEM) shares plummeted 5.05% during Friday's intraday trading session. The precision medicine company's stock experienced significant downward pressure following a major corporate financing announcement.

The decline is attributed to the company's pricing of an upsized private offering of $400 million worth of 0% convertible senior notes due in 2032. The offering was increased from an initially announced $350 million, with initial purchasers having an option to buy up to an additional $60 million of notes.

Convertible note offerings often lead to stock price declines due to investor concerns about potential shareholder dilution when the debt converts to equity. Tempus AI plans to use the net proceeds of approximately $384.1 million to repay $307.7 million of outstanding loans under its senior secured credit facilities, fund approximately $27.2 million of capped call transaction costs, and support general corporate purposes.